|
| 37758193 | A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. | Neuro Oncol | 2024 |
| 37758193 | A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. | Neuro Oncol | 2024 |
| 36599113 | Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. | J Clin Oncol | 2023 |
| 35419607 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. | Neuro Oncol | 2023 |
| 37944590 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Nat Med | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37899778 | Quantitative analysis of <i>MGMT</i> promoter methylation in glioblastoma suggests nonlinear prognostic effect. | Neurooncol Adv | 2023 |
| 38079020 | "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. | Acta Neuropathol | 2023 |
| 37342189 | A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma. | Front Oncol | 2023 |
| 36640127 | Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. | Neuro Oncol | 2023 |
| 36634606 | NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. | J Natl Compr Canc Netw | 2023 |
| 36633803 | Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis). | Curr Treat Options Oncol | 2023 |
| 36993741 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Res Sq | 2023 |
| 36686824 | Recent advances in the molecular prognostication of meningiomas. | Front Oncol | 2023 |
| 36599113 | Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. | J Clin Oncol | 2023 |
| 38079020 | "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. | Acta Neuropathol | 2023 |
| 37899778 | Quantitative analysis of <i>MGMT</i> promoter methylation in glioblastoma suggests nonlinear prognostic effect. | Neurooncol Adv | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37944590 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Nat Med | 2023 |
| 35419607 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. | Neuro Oncol | 2023 |
| 36993741 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Res Sq | 2023 |
| 37342189 | A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma. | Front Oncol | 2023 |
| 36686824 | Recent advances in the molecular prognostication of meningiomas. | Front Oncol | 2023 |
| 36640127 | Targeting the IL4 receptor with MDNA55 in patients with recurrent glioblastoma: Results of a phase IIb trial. | Neuro Oncol | 2023 |
| 36634606 | NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. | J Natl Compr Canc Netw | 2023 |
| 36633803 | Therapeutic and Supportive Effects of Cannabinoids in Patients with Brain Tumors (CBD Oil and Cannabis). | Curr Treat Options Oncol | 2023 |
| 34882581 | Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. | J Clin Invest | 2022 |
| 35395677 | Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. | Neuro Oncol | 2022 |
| 35759011 | Intratumor and informatic heterogeneity influence meningioma molecular classification. | Acta Neuropathol | 2022 |
| 35945463 | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Acta Neuropathol | 2022 |
| 35936751 | CDK 4/6 inhibitors for the treatment of meningioma. | Front Oncol | 2022 |
| 36322096 | Novel intraoperative strategies for enhancing tumor control: Future directions. | Neuro Oncol | 2022 |
| 35664553 | Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). | Neurooncol Adv | 2022 |
| 35402913 | Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. | Neurooncol Adv | 2022 |
| 35534562 | Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. | Nat Genet | 2022 |
| 34982879 | Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. | Neurosurgery | 2022 |
| 34882581 | Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. | J Clin Invest | 2022 |
| 35344029 | Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. | Clin Cancer Res | 2022 |
| 35402913 | Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. | Neurooncol Adv | 2022 |
| 35344029 | Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. | Clin Cancer Res | 2022 |
| 35534562 | Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. | Nat Genet | 2022 |
| 35759011 | Intratumor and informatic heterogeneity influence meningioma molecular classification. | Acta Neuropathol | 2022 |
| 35395677 | Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. | Neuro Oncol | 2022 |
| 35664553 | Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). | Neurooncol Adv | 2022 |
| 35936751 | CDK 4/6 inhibitors for the treatment of meningioma. | Front Oncol | 2022 |
| 36322096 | Novel intraoperative strategies for enhancing tumor control: Future directions. | Neuro Oncol | 2022 |
| 35945463 | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Acta Neuropathol | 2022 |
| 34982879 | Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. | Neurosurgery | 2022 |
| 34142085 | Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay. | Neurooncol Adv | 2021 |
| 34125374 | A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. | J Neurooncol | 2021 |